Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerToxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study.Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Pancreatic adenocarcinomaLow dose rate radiosensitization of hepatocellular carcinoma in vitro and in patientsPharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer.Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer modelQuantitative Detection of Nucleoside Analogues by Multi-enzyme Biosensors using Time-Resolved Kinetic Measurements.Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer.Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study.Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study.Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
P2860
Q26752368-4B0E5854-BAB5-486A-8E9D-ED8869EE9CF2Q28075540-A4F2B17A-8BAD-4A6B-941E-EC70B19E6B69Q33341524-3A181663-5326-4DDB-B736-DB96C2A98F62Q33343492-DD374791-29FB-463B-B977-C9E0B0D826A3Q33357700-BDD1E4ED-C348-4FF7-83BF-21F5C9702A36Q33410610-9C729115-434F-444F-90E2-ABA6E31A124FQ33566475-60FE2FB0-B735-4D3F-B38D-227DC87B5643Q33632330-CABFB36A-6130-4A23-8459-4251B357DBCDQ34140498-A66FE673-CDA0-427D-8278-CFD657117181Q34369205-DE3BE3AA-1374-499D-A7FE-13BA215E8859Q34425234-5385BB19-04FC-47C1-B43C-CD1834F2099DQ34439953-FA8CF8EE-8BF2-42D2-8B49-B0F005AC7185Q34810768-DD948A76-2883-4943-929F-6FD76EED7E10Q35773897-55828BFE-AB7E-4F16-8BDA-46C815AD354AQ35776091-905DA763-51E9-4EB4-8797-BA520BC63716Q35976361-3B1BC5AB-D7E8-4483-97B7-7144628F756DQ36099266-1515FE60-AAC1-4F24-B213-339625559769Q36348451-DB479882-6053-408F-B58F-53B3C80DD99EQ36612113-904247B3-DD59-418F-BE6C-55D6B648D848Q36614418-94D443C4-9E80-4B47-AB00-1299F2CB79ABQ36614865-D161F9DE-2A13-479A-901A-0D38F793AAB4Q36671639-1838B23A-C6AD-4B82-ADD9-C243AA524024Q36786939-75CFC17E-3467-457E-94AC-D6880D894FFFQ36831339-26D8005F-5ABE-4E6D-A759-058286D975F6Q37080484-FBB80F8B-9E14-4E75-84EF-81876B38E6ADQ37157395-A27CAD01-9921-42CA-B5E9-4338629767F0Q37500149-6F296946-9D2A-4C36-9300-A6D6410DF1B4Q37507420-7EDACBCB-BB07-4DD0-86F7-5BA8E8D194FAQ37939985-829F1D69-1DC1-4DD6-AE22-F68957A63F60Q38374457-B58BE0BC-F027-4C58-91C8-C157045027E2Q38673319-7FAEFDC4-B559-4308-A242-E0EEA77C8FEFQ38802097-BCAE261F-91C4-491C-8A87-0DB3CF4847C8Q39174079-0C94E96A-DA53-4E36-AA53-3A74F9999426Q39222400-0726AB6C-9027-4B07-A37C-E2AD8C957AA0Q39658359-F73CF39B-5073-4A76-806B-35FDF1E7F912Q39694952-C0561FD6-35B4-4375-8665-198ED9579FA9Q39851146-AD574815-FA64-4209-BE57-A74094130AF3Q39888116-E8391EB7-B46D-40AE-8175-BCDDFEEB3F04Q40345911-7E7EDB2E-FFAC-40F9-BF08-DD50B9879398Q40414815-D556EE59-A8B0-4C92-8B0E-04641819630E
P2860
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Saturation of 2',2'-difluorode ...... phase I trial of gemcitabine.
@en
type
label
Saturation of 2',2'-difluorode ...... phase I trial of gemcitabine.
@en
prefLabel
Saturation of 2',2'-difluorode ...... phase I trial of gemcitabine.
@en
P2093
P356
P1476
Saturation of 2',2'-difluorode ...... phase I trial of gemcitabine.
@en
P2093
J L Abbruzzese
P Tarassoff
R Grunewald
W Plunkett
P2888
P304
P356
10.1007/BF00685109
P577
1991-01-01T00:00:00Z
P6179
1048690607